![Patrick Kleyn](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrick Kleyn active positions
Companies | Position | Start | End |
---|---|---|---|
Ligon Discovery, Inc.
![]() Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Chief Tech/Sci/R&D Officer | 2010-06-15 | - |
Founder | 2009-11-05 | - | |
President | 2009-11-05 | - | |
Gemini Genomics Plc
![]() Gemini Genomics Plc Miscellaneous Commercial ServicesCommercial Services Part of Laboratory Corp. of America Holdings, Gemini Genomics Plc is a British company that provides clinical genomics services. The company is based in Cambridge, UK. The company was founded by Michael Edward Fitzgerald, Paul James Kelly. | Chief Tech/Sci/R&D Officer | 2009-11-05 | - |
Career history of Patrick Kleyn
Former positions of Patrick Kleyn
Companies | Position | Start | End |
---|---|---|---|
The Broad Institute, Inc.
![]() The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Statistics
International
United States | 3 |
United Kingdom | 2 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Founder | 1 |
President | 1 |
Sectoral
Commercial Services | 3 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
Ligon Discovery, Inc.
![]() Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Commercial Services |
Gemini Genomics Plc
![]() Gemini Genomics Plc Miscellaneous Commercial ServicesCommercial Services Part of Laboratory Corp. of America Holdings, Gemini Genomics Plc is a British company that provides clinical genomics services. The company is based in Cambridge, UK. The company was founded by Michael Edward Fitzgerald, Paul James Kelly. | Commercial Services |
The Broad Institute, Inc.
![]() The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Patrick Kleyn
- Experience